Pharmaceuticals

Chipscreen

Chipscreen released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 257.04 M, actual EPS CNY 0.0664

Chipscreen FY2026 Q1 Earnings Release on April 30 After-Market BJT

Chipscreen to release FY2025 earnings report on March 31 During-Market BJT, forecast revenue CNY 991 M, EPS CNY -0.17

Chipscreen released FY2025 Q4 earnings on February 26 During-Market (BJT), actual revenue CNY 235.38 M, actual EPS CNY -0.0482

Chipscreen released FY2025 Annual Earnings on February 26 During-Market (BJT), actual revenue CNY 910.06 M (forecast CNY 991 M), actual EPS CNY 0.125 (forecast CNY -0.17)

Chipscreen released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 267.56 M, actual EPS CNY 0.1008

Chipscreen released FY2025 9 Months Earnings on October 30 After-Market (BJT), Actual Revenue CNY 674.16 M, Actual EPS CNY 0.1733

Chipscreen to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

Chipscreen released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), Actual Revenue: CNY 406.6M, Actual EPS: CNY 0.0726

Chipscreen released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 244.33 M, actual EPS CNY 0.1195

Chipscreen to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

MicroCyte Subsidiary's CS231295 Clinical Trial Approved by FDA

MicroCyte Biotech Shares Surge 12.85%

MicroCy Biotech Conducted Block Trade

Micin Biotech Sees Net Profit Increase of 173% in H1 2025

Shenzhen MicroPort's Chidamide Drug Achieves Positive Results in Phase III Clinical Trials

MicroSigma Announces Successful Phase III Clinical Trial Results for Cedazuridine in Treating Diffuse Large B-Cell Lymphoma

MicroPort XCELL Biotech Shares Surge with Positive Analyst Report

MicroCyte Shares Up, Analysts Issue Buy Ratings

Micronas Biologicals CS231295 Clinical Trial Application Accepted by FDA

301235

中证转债

603979

688321

The China Securities Convertible Bond Index opened down 0.15%, reporting 528.92 points. Jin 25 Convertible Bond, Newtouch Convertible Bond, Zhenhua Convertible Bond, Chipscreen Convertible Bond, and Thalys Convertible Bond had the largest declines, falling by 5.24%, 4.04%, 3.02%, 2.74%, and 2.48%, respectively. NAIPU MINING Convertible Bond 02, Novoray Convertible Bond, HAOMEI Convertible Bond, TOPSCORE FASHION Convertible Bond, and Huakang Clean Convertible Bond had the largest increases, rising by 30.00%, 8.96%, 3.27%, 2.97%, and 1.74%, respectively

Wallstreetcn

Huakang Clean

JCHX

zhenhua chemical

NAIPU MINING

Newtouch

Bosera CSI Convertible Bond And Exchangeable Bond ETF

Thalys

Novoray

TOPSCORE FASHION

HAOMEI

Dr. Lu Xianping, Founder and Chairman of Shenzhen Chipscreen Biosciences, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards. This recognition highlights his contributions to innovation in the pharmaceutical industry. Dr. Lu, who holds a Ph.D. in Molecular Biology, founded Chipscreen in 2001 with a mission to develop affordable innovative drugs. His leadership led to the creation of significant drugs like Chidamide and Chiglitazar Sodium, which have improved treatment options for various cancers and diabetes. He has also contributed to enhancing China's pharmaceutical ecosystem and has donated over RMB 700 million in medicines to patients.

prnewswire

19:45 ET
			
			
				Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards

According to the announcement from Chipscreen, the company plans to repurchase shares worth between 10 million and 15 million yuan, with the repurchase price not exceeding 47.46 yuan per share, which will be used for the employee stock ownership plan or equity incentives

Zhitong

Chipscreen plans to repurchase shares for 10 million to 15 million yuan

Chipscreen announced that its revenue for the third quarter was 268 million yuan, a year-on-year increase of 49.51%; net profit was 41.1753 million yuan. Revenue for the first three quarters was 674 million yuan, a year-on-year increase of 40.12%; net profit was 70.7675 million yuan

Chipscreen: The net profit for the third quarter is 41.1753 million yuan

Chipscreen announced that Boao Bio plans to reduce its holdings by no more than 3% in the next 6 months due to strategic planning needs, totaling 12.2339 million shares. The reduction will be carried out through a combination of centralized bidding and block trading, with no more than 1% reduction every 90 days during the centralized bidding period and no more than 2% reduction every 90 days during the block trading period

Chipscreen: Bio-Thera Solutions plans to reduce its holdings by no more than 3% of shares

According to the Zhitong Finance APP, Chipscreen disclosed its semi-annual report for 2025, showing that the company achieved revenue of 407 million yuan during the reporting period, a year-on-year increase of 34.56%; the net profit attributable to the parent company was 29.59 million yuan, turning from loss to profit year-on-year; the net profit excluding non-recurring gains and losses was 20.32 million yuan, also turning from loss to profit year-on-year; the basic earnings per share were 0.0726 yuan

Chipscreen released its semi-annual performance, with a net profit attributable to the parent company of 29.59 million yuan, turning a profit compared to the same period last year

Chipscreen announced that its application for the issuance of A-shares to specific targets has been accepted by the Shanghai Stock Exchange. The review process for this application still requires approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission, and the final result and timeline remain uncertain. The company will disclose relevant information in a timely manner

Chipscreen: Application for the issuance of A-shares to specific targets has been accepted

Shenzhen-based company Chipscreen Biosciences Co., Ltd. has shared that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has recently obtained Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone was announced on July 31, 2025. The approval signifies a significant step forward for the company in advancing its pharmaceutical research and development efforts in the United States.

Unusual Whales

Chipscreen Biosciences' brain-penetrant CS231295 tablet gets FDA IND approval, advancing global clinical dev.

Chipscreen(688321.SH)